About

Score Pharma’s mission is to develop enhanced therapeutic antibodies to expand patient populations and provide better patient responses. Research has shown that afucosylated antibodies improve therapeutic outcomes. Our EnCore-5™ is a proprietary platform is designed to decrease the level of mAb fucosylation without the need for genetic modification, saving millions of dollars in costs and shortening the drug development process. With our proprietary technology, we are identifying multiple enhanced therapeutic candidates to address multiple conditions and diseases, including cancer, auto-immune and inflammatory diseases.